Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01692210 · ClinicalTrials.gov registry record
The Effect of Dexmedetomidine of the Immune System
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 20
- Enrollment target
NCT01692210: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT01692210 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01692210 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The goal of this research study is to learn about how dexmedetomidine (a standard of care sedative) affects your immune system (your defenses against cancer) by measuring your white blood cell levels before and after surgery.
Interventions
- DRUG Dexmedetomidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01692210
The ClinicalTrials.gov registry entry for NCT01692210 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexmedetomidine is the first listed.
NCT01692210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01692210 about?
NCT01692210 is a clinical study titled "The Effect of Dexmedetomidine of the Immune System". The goal of this research study is to learn about how dexmedetomidine (a standard of care sedative) affects your immune system (your defenses against cancer) by measuring your white blood cell levels before and after surgery.
What is the current status of trial NCT01692210?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2012-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01692210?
The interventions under investigation include: Dexmedetomidine (DRUG).
Who is sponsoring clinical trial NCT01692210?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.